RNA earnings analysis
What we found in RNA's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Atrium reported Q2 2026 collaboration revenue of $3.004 million and diluted EPS of $(1.18), with revenue lower than the supplied Q1 history of $20 million and continued substantial operating losses. The company advanced ATR 1072 toward a 37-participant Phase 1/2 trial, obtained FDA IND clearance in July 2026 and earned a $15 million BMS milestone. Liquidity is supported by $72.3 million of cash and $191.6 million of short-term investments, but management expects those resources to fund operations for only at least 12 months from filing and acknowledges potential additional financing needs.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Q2 collaboration revenue totaled $3.004M
- Q2 2026 collaboration revenue was $3.004 million, compared with $20 million of revenue in Q1 2026 in the supplied history, indicating a sequential decline in reported revenue.
- $15M BMS milestone supports liquidity
- The company received a $15 million BMS milestone payment in August 2026, providing a meaningful liquidity benefit for a clinical-stage company with no product revenue.
- ATR 1072 reached Phase 1/2 readiness
- ATR 1072 advanced into a planned 37-participant Phase 1/2 trial, and the FDA cleared the IND in July 2026; Health Canada also issued a No Objection Letter for planned Canadian sites.
- Disclosure controls assessed effective
- Management stated that disclosure controls and procedures were effective as of June 30, 2026, although processes and controls continue to evolve after becoming a standalone public company in February 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Continued losses and no product revenue
- The company reported a net loss of $20.186 million for Q2 2026 and net losses of $36.8 million for the six months ended June 30, 2026; management expects significant losses for the foreseeable future.
- Additional financing may be required
- Cash, cash equivalents and short-term investments were $72.3 million and $191.6 million, respectively, as of June 30, 2026, but management only committed to liquidity for at least 12 months from filing and stated that additional financing may be needed sooner than planned.
- Novartis-backed Avidity competition
- The filing identifies direct competition from Avidity and Novartis in cardiac markets; Novartis now owns Avidity, while the Avidity License Agreement grants Avidity a non-exclusive, worldwide, irrevocable, royalty-free license for cardiovascular products outside the Lilly and BMS collaborations.
- Early-stage clinical execution risk
- ATR 1072's planned Phase 1/2 trial is designed for 37 participants, highlighting enrollment and execution risk in rare cardiac diseases with small patient populations; the company has never completed a clinical trial or submitted a BLA.
- AI, privacy and cybersecurity exposure
- The filing adds or expands risks related to AI use, including potential cybersecurity exposure, flawed research outputs and evolving regulation; GDPR penalties can reach the greater of €20 million or 4% of worldwide annual gross revenue.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-1.18
- Segment
- Collaboration revenue: $3.004 million in Q2 2026; no additional operating segments were disclosed in the provided filing text.
What they said about what is next.
No numeric revenue or EPS guidance was provided. Management stated that existing cash, cash equivalents and short-term investments of $72.3 million and $191.6 million, respectively, are expected to fund operations for at least 12 months from the filing date.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 14, 2026
- Atrium Therapeutics, Inc. reported Q1 2026 results highlighting a substantial increase in collaboration revenue to $19.6 million, thanks to a milestone payment, while gross and operating margins were impacted by rising…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing RNA makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever